Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18321785 | 0.88 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL26666718 | 0.88 | HTR2A (0.56) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL24460937 | 0.87 | HTR2A (0.52) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL14512676 | 0.86 | HTR2A (0.54) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL26666747 | 0.85 | HTR2A (0.51) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL10870487 | 0.85 | CYP3A4 (0.50) | KMT2APKMSMN1; SMN2MAPTNPC1 | |
| SCHEMBL5491110 | 0.85 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL2531122 | 0.83 | HTR2A (0.49) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL1421471 | 0.83 | HTR2A (0.57) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL409598 | 0.82 | HTR2A (0.59) | HTR2ABCL9CTNNB1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1908 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3836273-B1 | ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERIES AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | HYUNDAI MOTOR CO LTD (KR) | 2025-03-19 | — | — | EP | claimed |
| EP-2991655-B1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-10 | — | — | EP | claimed |
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| US-11444327-B2 | Electrolyte solution for lithium secondary batteries and lithium secondary battery including the same | HYUNDAI MOTOR COMPANY (KR) | 2022-09-13 | — | — | US | claimed |
| US-20210184262-A1 | ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERIES AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | KIA MOTORS CORPORATION (KR) | 2021-06-17 | — | — | US | claimed |
| EP-3836273-A1 | ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERIES AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | HYUNDAI MOTOR COMPANY (KR) | 2021-06-16 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3063164-B1 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | OTSUKA PHARMA CO LTD (JP) | 2018-12-05 | — | — | EP | claimed |
| US-9856225-B2 | Substituted phenazines as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-01-02 | — | — | US | claimed |
| EP-2550285-B1 | TRIOXACARCINS AND USES THEREOF | HARVARD COLLEGE (US) | 2017-07-19 | — | — | EP | claimed |
| US-20150376201-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-31 | — | — | US | claimed |
| CN-112993404-B | Electrolyte solution for lithium secondary battery and lithium secondary battery comprising same | 现代自动车株式会社 | 2026-03-13 | — | — | CN | disclosed |
| EP-3836273-B1 | ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERIES AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | HYUNDAI MOTOR CO LTD (KR) | 2025-03-19 | — | — | EP | disclosed |
| CN-118355117-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-6608192-B1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-08-19 | — | — | US | disclosed |
| EP-1107969-A2 | COLLECTIONS OF COMPOUNDS | Spirogen Limited (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012506-A2 | COLLECTIONS OF COMPOUNDS | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| US-5789595-A | ANTICOAGULANTS | TERUMO KABUSHIKI KAISHA (JP) | 1998-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376201-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | CTTN, TEK, FLT1 | HTR2A 4246/4885BCL9 3726/4885CTNNB1 2279/4885 |
| US-20210184262-A1 | ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERIES AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | NCL, NPM1, CACNA2D1 | HTR2A 4837/4885BCL9 490/4885CTNNB1 152/4885 |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | HTR2A 3718/4885BCL9 48/4885CTNNB1 981/4885 |
| US-11444327-B2 | Electrolyte solution for lithium secondary batteries and lithium secondary battery including the same | NCL, PSPH, NNT | HTR2A 4812/4885BCL9 452/4885CTNNB1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.